GYKI 52466 and ischemia-evoked neurotransmitter amino acid release from rat cerebral cortex.
The effects of the benzodiazepine derivative GYKI 52466 on ischemia-evoked neurotransmitter amino acid release were evaluated in a rat four vessel occlusion model with cerebral cortical cups. Following intravenous GYKI 52466 administration (10 mg kg-1 bolus followed by 10 mg kg-1 60 min-1 infusion) glutamate, aspartate and GABA release into cerebral cortical superfusates was enhanced by ischemia to a comparable extent to that observed in control ischemic rats. These results suggest that the protective action of GYKI 52466 against cerebral cortical ischemic injury is unlikely to be due to a selective reduction in extracellular glutamate levels, but is rather, a result of the recognized ability of this compound to block non-NMDA receptors.
Phillis
J W
JW
Department of Physiology, Wayne State University School of Medicine, Detroit, MI 48201.
Smith-Barbour
M
M
Perkins
L M
LM
O'Regan
M H
MH
D000596:Amino Acids / Q000378:metabolism*; D000818:Animals; D014151:Anti-Anxiety Agents; D001569:Benzodiazepines / Q000494:pharmacology*; D001784:Blood Gas Analysis; D001794:Blood Pressure / Q000187:drug effects; D002545:Brain Ischemia / Q000378:metabolism*; D002540:Cerebral Cortex / Q000187:drug effects / Q000378:metabolism*; D005110:Extracellular Space / Q000187:drug effects / Q000378:metabolism; D008297:Male; D009125:Muscle Relaxants, Central / Q000494:pharmacology*; D018377:Neurotransmitter Agents / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley
D000596:Amino Acids; D014151:Anti-Anxiety Agents; D009125:Muscle Relaxants, Central; D018377:Neurotransmitter Agents; C061950:GYKI 52466; D001569:Benzodiazepines